Idarubicinol myelotoxicity: A comparison of in vitro data with clinical outcome in patients treated with high-dose idarubicin

British Journal of Cancer

Volumn 82, Issue 3, 2000, Pages 524-528

  Corsini, C ^a   Ghielmini, M ^b   Mancuso, P ^a   Tealdo, F ^a   Paolucci, M ^a   Zucchetti, M ^c   Ferrucci, P F ^a   Cocorocchio, E ^a   Mezzetti, M ^a   Mori, A ^d   Riggi, M ^d   D'Incalci, M ^c   Martinelli, G ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b OSPEDALE SAN GIOVANNI   (Switzerland)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d PFIZER INC   (United States)

Author keywords

CFU GM growth inhibition; Haematotoxicity; High dose chemotherapy; Idarubicin; Idarubicinol

Indexed keywords

CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; IDARUBICINOL; MELPHALAN;

ADULT; ARTICLE; BONE MARROW TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; COLONY FORMING UNIT GM; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; LYMPHOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0033967369     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.1999.0957     Document Type: Article

References (27)

1. Broggini M, Italia C, Colombo T, Marmonti L and Donelli MG (1984) Activity and distribution of i.v. and oral 4-demethoxydaunorubicin in murine experimental tumours. Cancer Treat Rep 68: 739-747
2. Camaggi CM, Strocchi E, Carisi P, Martoni A, Tononi A, Guaraldi M, Strolin-Benedetti M, Efthymiopoulos C and Pannutti F (1992) Idarubicin metabolism and pharmacokinetic after intravenous and oral administration in cancer patients. A cross-over study. Cancer Chemother Pharmacol 30: 307-316
3. Campbell AD and Wicha MS (1988) Extracellular matrix and the haematopoietic microenvironment. J Lab Clin Med 112: 140-146
4. Case DC, Gerber MC, Gams RA, Crawford J, Votaw ML, Higano CS, Pruitt BT and Gould J (1993) Phase II study of intravenous idarubicin in unfavourable non-Hodgkin's lymphoma. Leuk Lymphoma 10: 73-79
5. Chisesi T, Capnist G, De Dominicis E and Dini E (1988) A phase II study of idarubicin (4-demethoxydaunorubicin) in advanced myeloma. Eur J Cancer Clin Oncol 24: 681-684
6. Coutinho LH, Gilleece MH, De Winter EA, Will A and Testa NG (1993) Clonal and long-term cultures using human bone marrow. In: Haemopoiesis: a Practical Approach, Testa NG, Molineux G (eds), pp. 75-105. Oxford University Press: New York
7. Dodion P, Sanders C, Rombaut W, Mattelaer MA, Rozeneweig M, Styckmans P and Kenis Y (1987) Effect of daunorubicin, carminomycin, idarubicin and 4-demethoxydaunorubicinol against normal myeloid stem cells and human malignant cells in vitro. Europ J Cancer Clin Oncol 23: 1909-1914
8. Dufour P, Mors R and Lamy T (1993) Idarubicin (IDA) and high-dose aracytine (HD-AraC): a new promising salvage treatment in relapsed or refractory non Hodgkin's lymphoma. Proc Am Soc Clin Oncol 12: 364 (abstract 1229)
9. Engert A (1995) Treatment of large cell lymphoma in second relapse. Lymphoma the next question. October 19-21, San Antonio. TX (abstract)
10. Garay G, Dupont J, Dragosky M, Nucifora E, Cacchione R, Schnidring P, Fernandez J, Abel-Alzueta A, Riveros D, Noviello V, Beguelin R, Campestri R, Albera C, Nicastro M and Triguboff E (1997) Combination salvage chemotherapy with MIZE (mesna-ifosfamide, idarubicin and etoposide) for relapsing or refractory lymphoma. Leuk Lymphoma 26: 595-602
11. Ghielmini M, Bosshard G, Capolongo L, Geroni MC, Pesenti E, Torri V, D'Incalci M, Cavalli F and Sessa C (1997) Estimation of the haematological toxicity of minor groove alkylators using tests on human cord blood cells. Br J Cancer 75: 878-883
12. Ghielmini M, Colli E, Bosshard G, Pennella G, Geroni C, Torri W, D'Incalci M, Cavalli F and Sessa C (1998) Hematotoxicity on human bone marrow- and umbilical cord blood-derived progenitor cells and in vitro therapeutic index of methoxymorpholinyldoxorubicin and its metabolite. Cancer Chemoth Pharmacol 42: 235-240
13. Gianni AM, Siena S, Bregni M, Lombardi F, Gandola L, Di Nicola M, Magni M, Peccatori F, Valagussa P and Bonadonna G (1993) High-dose sequential chemotherapy with peripheral blood progenitor cell support for relapsed or refractory Hodgkin's disease. A 6-year update. Ann Oncol 4: 889-891
14. Greenberg BR, Reynolds RD, Charron CB, Squillace KM, Lessins LS, Case DC and Gams RA (1993) Treatment of myelodysplastic syndrome with daily oral idarubicin. Cancer 71: 1989-1992
15. Gribaldo L, Bueren J and Deldar A (1996) The use of in vitro systems for evaluating haematotoxicity. Atla 24: 211-231
16. Kuffel M, Reid JM and James MM (1992) Anthracyclines and their C-13 alcohol metabolites. Growth inhibition and DNA damage following incubation with human tumor cells in culture. Cancer Chemother Pharmacol 30: 51-57
17. Leglise MC, Darodes de Taìly P, Vignot JL, Le Bot MA, Le Roux AM and Richè C (1996) A cellular model for drug interactions in hematopoiesis: the use of human umbilical cord blood progenitors as a model for the study of drug-related myelosuppression of normal hematopoiesis. Cell Biol Toxicol 12: 39-53
18. Liu LF, Rowe TC, Yang L, Tekey KM and Chen GL (1983) Cleavage of DNA by mammalian DNA topoisomerase II. J Biol Chem 258: 15365-15370
19. Minderman H, Linssen P, Van der Lely N, Wessels J, Boezeman J, De Witte F and Haanen C (1994) Toxicity of idarubicin and doxorubicin towards normal and leukemic human bone marrow progenitors in relation to their proliferative status. Leukemia 8: 382-387
20. Muus P, Donnelly P, Schattenberg A, Linssen P, Minderman H, Dompeling E and De Witte T (1993) Idarubicin-related side effects in recipients of T-cell-depleted allogeneic bone marrow transplants are schedule dependent. Semin Oncol 20: 47-52.
21. Parchment RE, Gordon M, Grieshaber CK, Sessa C, Volpe D and Ghielmini M (1998) Predicting hematological toxicity (myelosuppression) of cytotoxic drug therapy from in vitro tests. Ann Oncol 9: 357-364
22. Robert J (1993) Clinical pharmacokinetics of idarubicin. Clin Pharmacokinet 24: 275-288
23. Salmon SE, Liu RM and Casazza AM (1981) Evaluation of new anthracycline analogs with the human tumor stem cell assay. Cancer Chemother Pharmacol 6: 103-110
24. Schott B and Robert J (1989) Comparative cytotoxicity, DNA synthesis inhibition and drug incorporation of eight anthracyclines in a model of doxorubicin-sensitive and -resistant rat glioblastoma cells. Biochem Pharmacol 38: 167-172
25. Twelves CJ (1995) Oral idarubicin in solid tumors chemotherapy. Clin Drug Invest 9 (Suppl. 2): 39-54
26. Van Der Lely N, De Witte T, Raemaekers J, Schattenberg A and Haanen C (1989) Anthracyclines added to the conditioning regimen for allogeneic bone marrow transplantation are associated with a slower haematopoietic recovery. Bone Marrow Transplant 4: 163-166
27. Vogler WR, Velez Garcia E, Weiner RS, Flaum MA, Bartolucci AA, Omura GA, Gerber MC and Banks PL (1992) A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group study. J clin Oncol 10: 1103-1111